Gerson Peltz

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.”.

Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10041

N/A

0DataRank · unranked

0 citations

Yaël P. Mossé, Kimberly Kayser, Yueh‐Yun Chi, Marc Chioda, Holger Thurm +14 more